

Saskatchewan Immunization Manual Amendments June 2013

Instruction: Please remove and discard the corresponding pages in each chapter section and insert the amended pages as noted below in each corresponding chapter section dated **June 2013**

Chapter 5 Immunization Schedules

- pp. 5-6 (dated April 2013) Sections 1.4 and 1.5
 - Footnote reinstated to section 1.4 #11 and section 1.5 #16, as was erroneously removed when pages last updated. “Individuals who are cohort-eligible for a 2-dose varicella series who have a history of either physician diagnosed herpes zoster or lab confirmed varicella after their first varicella-containing vaccine dose do not require a second varicella-containing vaccine dose as they will have developed immunity. If disease history is uncertain provide a second dose of varicella-containing vaccine”.

Chapter 7 Immunization of Special Populations

- ToC first page (dated March 2013)
 - Rotavirus removed from title in section 1.4.1 - Consideration for MMR and Varicella or Immunization of Immunocompromised Individuals.
- p.22 (dated April 2013) Section 2.3.1A: Publicly Funded Vaccines during Pregnancy
 - Tdap wording clarified to indicate that a MHO consultation required prior to the administration of Tdap to a pregnant women in high-risk situations.
- p.22 (dated March 2013) Section 2.4
 - The following statement added to bullet #7: It is advisable to administer the vaccine approximately 3-4 hours after the anti-haemophilia therapy which decreases the risk of bleeding and haematoma. If bleeding does not stop after administering the vaccine, contact the MHO for further assistance (more anti-haemophilia therapy may be needed).

Chapter 8 Administration of Biological Products

- Table of Contents (first page dated March 2013)
 - New section added: 1.37 Prefilled Syringe-Vaccine Vial Format added.
- Table of Contents (second page dated April 2013)
 - Revised to accommodate changes to first ToC page.
- p.6 (dated April 2012)
 - New section added: 1.37 Prefilled Syringe-Vaccine Vial Format added.

Chapter 9 Management of Biological Products

- p.26 (dated February 2013) Section 4.1.2
 - Bullet #3 – PHN consultant fax number corrected.

Chapter 10 Biological Products

- Toc page 1 (dated April 2013)
 - Vaqta Jr. removed from HA heading as does not have own product monograph anymore.
- HB vaccine dosage/formulation options for HIV+ (dated April 2013)
 - Spacing between doses 3-4 for adults corrected to 16 weeks, not 26 weeks.
- Adacel-polio (dated August 2012) indicated as a non-publicly funded vaccine.
- MMR II (dated June 2012) and Priorix (dated June 2012) – indications amended to reflect that adults born since 1970-01-01 qualify for 2 MMR doses.

- New product monograph updates for:
 - Boostrix
 - Cervarix
 - HIBERIX
 - Menjugate
 - INFANRIX-hexa
 - Varilrix
 - Vaqta (Vaqta Jr, removed as not noted as having separate monograph)
 - RotaTeq
 - Vivotif
 - Zostavax
 - Menveo
 - Priorix
 - SYNFLORIX

Chapter 13 Principles of Immunology

- p.19 (dated April 2012) Resources
 - Both web links updated

Chapter 14 Appendices

- p. 21 (dated January 2013)
 - Men-C-ACYW-135 fact sheet date changes to May 2013